Regeneron beats results estimates on demand for eczema treatment, eye drug
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...
Health on MSN12mon
10 Treatments for Atopic Dermatitis (Eczema)
Here's how to find relief if you have eczema.Medically reviewed by Brendan Camp, MDAtopic dermatitis (AD) is a chronic ...
pharmaphorum1y
Sanofi's Dupixent funded in Wales and Scotland for adolescents with eczema
Sanofi’s Dupixent (dupilumab ... the first topical treatment specifically approved for chronic hand eczema (CHE). The AI effect in pharma commercial strategy: From data to re ...
Managed Healthcare Executive4d
Ebglyss Shows Improvement in Atopic Dermatitis Patients Who Stopped Dupixent
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
Yahoo Finance24d
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Sanofi SA (NASDAQ:SNY) / Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Dupixent ...
pharmaphorum16d
NICE okays NHS funding for MS and eczema drugs
changing its mind in guidance for the multiple sclerosis and eczema drugs. NICE had previously rejected Roche's Ocrevus (ocrelizumab) for multiple sclerosis and Sanofi's Dupixent (dupilumab) ...
Benzinga.com24d
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. Ebglyss was also approved in the European Union in 2023 and ...